Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 561Leukemia 282Precursor Cell Lymphoblastic Leukemia-Lymphoma 235Lymphoma 160Myelodysplastic Syndromes 111Burkitt Lymphoma 91Congenital Abnormalities 86Lymphoma, Non-Hodgkin 85Leukemia, Monocytic, Acute 84Leukemia, Myelomonocytic, Acute 82Lymphoma, Large B-Cell, Diffuse 80Leukemia, Erythroblastic, Acute 75Leukemia, Megakaryoblastic, Acute 72Recurrence 70Lymphoma, Mantle-Cell 70Lymphoma, Follicular 49Hodgkin Disease 44Leukemia, Myelomonocytic, Chronic 43Leukemia, Biphenotypic, Acute 43Lymphoma, Large-Cell, Immunoblastic 37Blast Crisis 37Anemia, Refractory, with Excess of Blasts 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 35Leukemia, Lymphocytic, Chronic, B-Cell 33Myeloproliferative Disorders 30Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 28Lymphoma, B-Cell, Marginal Zone 24Leukemia, Myeloid, Chronic-Phase 23Leukemia, Eosinophilic, Acute 23Leukemia, Basophilic, Acute 22

Interventions

fludarabine phosphate 4Sensitivity and Specificity 3Cyclophosphamide 3Antigens, CD19 3ibrutinib 2Whole-Body Irradiation 2Mycophenolic Acid 2Immunotherapy, Adoptive 2Etoposide 2pevonedistat 1obinutuzumab 1nelarabine 1letermovir 1carmustine, poliferprosan 20 drug combination 1Tacrolimus 1Stem Cell Transplantation 1Specimen Handling 1Pharmacogenomic Variants 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Leukapheresis 1Lenalidomide 1Hematopoietic Stem Cell Transplantation 1Cytarabine 1Cyclosporins 1Cyclosporine 1Carmustine 1Blood Component Removal 1Biopsy 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, B-Cell × Cytarabine × Clear all
NCT01008462 2019-06-11

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Fred Hutchinson Cancer Center

Phase 2 Completed
16 enrolled 15 charts
LymphoidOther hematologic neoplasmPlasma cell

Chromosome 17 deletion, Hodgkin Disease, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡